Zhejiang Xianju Pharmaceutical Co.,Ltd.'s (SZSE:002332) Stock Has Fared Decently: Is the Market Following Strong Financials?
Zhejiang Xianju Pharmaceutical Co.,Ltd.'s (SZSE:002332) Stock Has Fared Decently: Is the Market Following Strong Financials?
Zhejiang Xianju PharmaceuticalLtd's (SZSE:002332) stock is up by 9.5% over the past three months. Since the market usually pay for a company's long-term financial health, we decided to study the company's fundamentals to see if they could be influencing the market. Specifically, we decided to study Zhejiang Xianju PharmaceuticalLtd's ROE in this article.
浙江仙居藥業有限公司(深圳證券交易所:002332)的股票在過去三個月中上漲了9.5%。由於市場通常爲公司的長期財務狀況買單,因此我們決定研究公司的基本面,看看它們是否會影響市場。具體而言,我們決定在本文中研究浙江仙居藥業有限公司的投資回報率。
Return on Equity or ROE is a test of how effectively a company is growing its value and managing investors' money. Put another way, it reveals the company's success at turning shareholder investments into profits.
股本回報率或投資回報率是對公司價值增長和管理投資者資金的有效性的考驗。換句話說,它揭示了該公司成功地將股東投資轉化爲利潤。
Check out our latest analysis for Zhejiang Xianju PharmaceuticalLtd
查看我們對浙江仙居藥業有限公司的最新分析
How To Calculate Return On Equity?
如何計算股本回報率?
The formula for ROE is:
投資回報率的公式是:
Return on Equity = Net Profit (from continuing operations) ÷ Shareholders' Equity
股本回報率 = 淨利潤(來自持續經營)÷ 股東權益
So, based on the above formula, the ROE for Zhejiang Xianju PharmaceuticalLtd is:
因此,根據上述公式,浙江仙居藥業有限公司的投資回報率爲:
12% = CN¥687m ÷ CN¥5.7b (Based on the trailing twelve months to September 2023).
12% = 6.87億元人民幣 ÷ 57億元人民幣(基於截至2023年9月的過去十二個月)。
The 'return' refers to a company's earnings over the last year. So, this means that for every CN¥1 of its shareholder's investments, the company generates a profit of CN¥0.12.
“回報” 是指公司去年的收益。因此,這意味着該公司每投資1元人民幣,就會產生0.12元人民幣的利潤。
What Is The Relationship Between ROE And Earnings Growth?
投資回報率與收益增長之間有什麼關係?
So far, we've learned that ROE is a measure of a company's profitability. Depending on how much of these profits the company reinvests or "retains", and how effectively it does so, we are then able to assess a company's earnings growth potential. Assuming everything else remains unchanged, the higher the ROE and profit retention, the higher the growth rate of a company compared to companies that don't necessarily bear these characteristics.
到目前爲止,我們已經了解到,投資回報率是衡量公司盈利能力的指標。然後,根據公司對這些利潤進行再投資或 “保留” 的金額及其有效性,我們就能評估公司的盈利增長潛力。假設其他一切都保持不變,那麼與不一定具有這些特徵的公司相比,投資回報率和利潤保留率越高,公司的增長率就越高。
A Side By Side comparison of Zhejiang Xianju PharmaceuticalLtd's Earnings Growth And 12% ROE
浙江仙居製藥有限公司的收益增長和12%的投資回報率的並排比較
To start with, Zhejiang Xianju PharmaceuticalLtd's ROE looks acceptable. Further, the company's ROE compares quite favorably to the industry average of 8.5%. This probably laid the ground for Zhejiang Xianju PharmaceuticalLtd's moderate 19% net income growth seen over the past five years.
首先,浙江仙居藥業有限公司的投資回報率似乎可以接受。此外,該公司的投資回報率與行業平均水平的8.5%相比相當不錯。這可能爲浙江仙居藥業有限公司在過去五年中實現19%的溫和淨收入增長奠定了基礎。
As a next step, we compared Zhejiang Xianju PharmaceuticalLtd's net income growth with the industry, and pleasingly, we found that the growth seen by the company is higher than the average industry growth of 11%.
下一步,我們將浙江仙居藥業有限公司的淨收入增長與該行業進行了比較,令人高興的是,我們發現該公司的增長高於行業平均增長11%。
![past-earnings-growth](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20240102/0-6341edfcbd221fc86d9e438d357c842e-0-a06261aeee4bdedc34644e19214025fc.png/big)
Earnings growth is a huge factor in stock valuation. The investor should try to establish if the expected growth or decline in earnings, whichever the case may be, is priced in. By doing so, they will have an idea if the stock is headed into clear blue waters or if swampy waters await. Is Zhejiang Xianju PharmaceuticalLtd fairly valued compared to other companies? These 3 valuation measures might help you decide.
收益增長是股票估值的重要因素。無論如何,投資者應設法確定預期的收益增長或下降是否已計入其中。通過這樣做,他們將知道股票是走向清澈的藍色海水還是沼澤水域在等着呢。與其他公司相比,浙江仙居藥業有限公司的估值是否合理?這3種估值指標可能會幫助您做出決定。
Is Zhejiang Xianju PharmaceuticalLtd Making Efficient Use Of Its Profits?
浙江仙居藥業有限公司是否在有效利用其利潤?
In Zhejiang Xianju PharmaceuticalLtd's case, its respectable earnings growth can probably be explained by its low three-year median payout ratio of 25% (or a retention ratio of 75%), which suggests that the company is investing most of its profits to grow its business.
以浙江仙居製藥有限公司爲例,其可觀的盈利增長可以用其三年中位數派息率低至25%(或75%的留存率)來解釋,這表明該公司正在將大部分利潤投資於業務增長。
Besides, Zhejiang Xianju PharmaceuticalLtd has been paying dividends for at least ten years or more. This shows that the company is committed to sharing profits with its shareholders. Based on the latest analysts' estimates, we found that the company's future payout ratio over the next three years is expected to hold steady at 28%. As a result, Zhejiang Xianju PharmaceuticalLtd's ROE is not expected to change by much either, which we inferred from the analyst estimate of 13% for future ROE.
此外,浙江仙居藥業有限公司已經派發股息至少十年或更長時間。這表明該公司致力於與股東分享利潤。根據分析師的最新估計,我們發現該公司未來三年的派息率預計將穩定在28%。因此,浙江仙居製藥有限公司的投資回報率預計也不會有太大變化,我們從分析師對未來投資回報率爲13%的估計中推斷了這一點。
Summary
摘要
In total, we are pretty happy with Zhejiang Xianju PharmaceuticalLtd's performance. Specifically, we like that the company is reinvesting a huge chunk of its profits at a high rate of return. This of course has caused the company to see substantial growth in its earnings. On studying current analyst estimates, we found that analysts expect the company to continue its recent growth streak. To know more about the latest analysts predictions for the company, check out this visualization of analyst forecasts for the company.
總的來說,我們對浙江仙居藥業有限公司的表現非常滿意。具體而言,我們喜歡該公司以高回報率再投資其利潤的很大一部分。當然,這導致該公司的收益大幅增長。在研究分析師當前的估計時,我們發現分析師預計該公司將繼續保持最近的增長勢頭。要詳細了解分析師對公司的最新預測,請查看該公司的分析師預測的可視化。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對這篇文章有反饋嗎?對內容感到擔憂?直接聯繫我們。 或者,給編輯團隊 (at) simplywallst.com 發送電子郵件。
Simply Wall St 的這篇文章本質上是籠統的。我們僅使用公正的方法提供基於歷史數據和分析師預測的評論,我們的文章並非旨在提供財務建議。它不構成買入或賣出任何股票的建議,也沒有考慮到您的目標或財務狀況。我們的目標是爲您提供由基本數據驅動的長期重點分析。請注意,我們的分析可能不會考慮最新的價格敏感型公司公告或定性材料。華爾街只是沒有持有上述任何股票的頭寸。